Evaluating 18F-AlF-FAPI PETCT for Diagnosing and Monitoring Thyroid Eye Disease Activity

What this Trial Is About

Researchers are evaluating the use of 18F-AlF-FAPI PETCT scans to assess activity in patients with Thyroid Eye Disease TED, a condition involving fibroinflammatory changes. This study aims to compare this newer imaging method with the traditional 99mTc-DTPA SPECTCT scan to see which is better for diagnosing TED, monitoring therapy response, and following up with patients. The goal is to understand whether 18F-AlF-FAPI PETCT provides superior diagnostic accuracy and useful information about disease activity. Participants with TED will undergo both 18F-AlF-FAPI PETCT and 99mTc-DTPA SPECTCT scans within a 10-day period. The scans measure uptake in the extraocular muscles using different metrics to evaluate disease activity. Researchers will analyze these imaging results alongside clinical data to assess how well each scan detects TED activity and responds to therapy changes. This process involves quantifying uptake using SUV metrics and uptake ratios for comparison. During the study, participants will be monitored for diagnostic accuracy and therapy response over an average of 6 to 12 months. Researchers will collect clinical information and imaging data to explore correlations between scan results and disease status. The study includes safety and follow-up assessments, with participants providing informed consent and cooperating with imaging procedures. The total involvement duration varies depending on follow-up needs.

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease